BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb
In This Article:
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.
Terms and Privacy Policy